Localised prostate cancer

What is localised prostate cancer?

Localised prostate cancer is cancer that’s inside the prostate and hasn’t spread to other parts of the body. You may also hear it called early or organ-confined prostate cancer, or stage T1 or T2 prostate cancer.

Most localised prostate cancer grows slowly – or doesn’t grow at all – and has a low risk of spreading. So it may never cause you any problems or affect how long you live. Because of this, localised prostate cancer might not need treatment. You might be able to have your cancer monitored with regular check-ups instead. This is to make sure the cancer isn’t growing more quickly than expected.

But some men will have cancer that grows quickly and has a high risk of spreading. This is more likely to cause problems and needs treatment to stop it spreading outside the prostate.

gp

Localised prostate cancer fact sheet

This fact sheet is for anyone who had been diagnosed with localised prostate cancer.

Download or order fact sheet

What do my test results mean?

Your results will help your doctor understand how quickly your cancer might grow and whether it has spread. This will help you and your doctor to discuss what treatments might be suitable for you.

Read more about what your test results might mean.

What are my treatment options?

Most localised prostate cancer often grows slowly and might not need treatment. You may be able to have your cancer monitored with regular check-ups instead. If you decide to have treatment, it will usually aim to get rid of the cancer.

The two ways of monitoring localised prostate cancer are:

The main treatments for localised prostate cancer are:

You might also be offered high-intensity focused ultrasound (HIFU) or cryotherapy, but they are less common and only available in specialist centres in the UK or as part of a clinical trial.

Your doctor or nurse will talk you through your treatment options and help you choose the right type of monitoring or treatment for you. You might not be able to have all of the treatments listed. There’s no overall best treatment for localised prostate cancer, and each one has its own advantages and disadvantages. Read more about choosing a treatment.

What will happen after my treatment?

You will have regular check-ups during and after your treatment to check how well it is working. You may hear them called follow-up appointments. You’ll have regular PSA blood tests – ask the people treating you how often you’ll have these. If your PSA level goes down this usually suggests your treatment is working.

Tell your doctor or nurse about any side effects you’re getting. There are usually ways to manage side effects.

Make sure you have the details of someone to contact if you have any questions or concerns between check-ups. This might be your specialist nurse or key worker. You can also speak to our Specialist Nurses.

Read more about follow-up after prostate cancer treatments.

What is my outlook?

Many men will want to know how successful their treatment is likely to be. This is sometimes called your outlook or prognosis. No one can tell you exactly what will happen, as it will depend on many things, such as the stage of your prostate cancer and how quickly it might grow, your CPG (Cambridge Prognostic Group) your age, and any other health problems. Speak to your doctor about your own situation.

Most localised prostate cancer is slow-growing and may not need treatment or shorten a man’s life. For many men who have treatment for localised prostate cancer, the treatment will get rid of the cancer. For some men, treatment may be less successful and the cancer may come back. If this happens, you might need further treatment.

For more information about the outlook for men with prostate cancer, visit Cancer Research UK. The figures they provide are a general guide and they cannot tell you exactly what will happen to you. Speak to your doctor or nurse about your own situation.

Where can I get support?

Being diagnosed with any kind of prostate cancer can be frightening and overwhelming. No matter what you’re feeling or thinking, there is support available if you want it. You can speak to our Specialist Nurses, in confidence or chat with them online. Our Dealing with prostate cancer page looks at things you can do to help yourself and people who can help.

Visit our wellbeing hub for information to help support you in looking after your emotional, mental, and physical wellbeing. If you are close to someone with prostate cancer, find out more about how you can support someone with prostate cancer and where to get more information.

Questions to ask your doctor or nurse

  • What is my Gleason score?
  • What is the stage of my cancer?
  • What is my CPG (Cambridge Prognostic Group) score?
  • What treatments are suitable for me?
  • Could my cancer be monitored instead?
  • How quickly do I need to make a decision?
  • What are the advantages and disadvantages of each treatment?
  • What are the side effects?
  • How effective is my treatment likely to be?
  • What is the risk of my cancer coming back after treatment?
  • Can I see the results of treatments you’ve carried out?
  • Can I get copies of all my test results and letters about my treatment?
  • Are all of the treatments available at my local hospital?
  • If not, how could I have them?
  • Can I join any clinical trials?
  • If I have any questions or get any new symptoms, who should I contact?

References

Updated: September 2023|To be reviewed: September 2026

  • Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017 Jan;
  • Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama. 2005;293(17):2095–101.
  • Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. Eur Urol. 2013 May;63(5):800–9.
  • Berney DM. The case for modifying the Gleason grading system. BJU Int. 2007;100(4):725–6.
  • Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, et al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr;69(4):693–703.
  • British Medical Association. Patients recording consultations [Internet]. Patients recording consultation. 2021 [cited 2023 Mar 29]. Available from: https://www.bma.org.uk/advice-and-support/ethics/confidentiality-and-health-records/patients-recording-consultations
  • Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–501.
  • Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011 Nov 8;105:S52–73.
  • Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol. 2012 Jan 6;23(7):1665–71.
  • Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.
  • Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol. 2014 Feb 1;32(4):335–46.
  • Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, et al. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec;68(6):1076–82.
  • Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Sep 14;
  • Hechtman LM. Clinical Naturopathic Medicine [Internet]. Harcourt Publishers Group (Australia); 2014 [cited 2015 Jul 21]. 1610 p. Available from: http://www.bookdepository.com/Clinical-Naturopathic-Medicine-Leah-Hechtman/9780729541923
  • Hegarty J, Walsh E, Harry Comber, Tony Fitzgerald, Kazer MW. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev. 2010;
  • Henson CC, Burden S, Davidson SE, Lal S. Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy. Cochrane Database Syst Rev [Internet]. 2013 [cited 2014 Nov 18];(11). Available from: http://doi.wiley.com/10.1002/14651858.CD009896.pub2
  • Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence After Radical Prostatectomy: Biology or Technique? Results from the SEARCH Database. Eur Urol. 2012 Nov;62(5):910–6.
  • Hu MB, Xu H, Bai PD, Jiang HW, Ding Q. Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients. Med Oncol Northwood Lond Engl. 2014 Feb;31(2):829.
  • Humphrey P, Moch H, Cubilla A, Reuter V, Ulbright T. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and BladderTumours [Internet]. 2016. Available from: http://www.europeanurology.com/article/S0302-2838%2816%2900205-0/abstract/the-2016-who-classification-of-tumours-of-the-urinary-system-and-male-genital-organs-part-b-prostate-and-bladder-tumours
  • Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.
  • Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017 Jun 10;
  • Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. J Pain Symptom Manage. 2012 Jan;43(1):96–110.
  • Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2011;110(4):492–8.
  • Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: A systematic review of non-pharmacological interventions. Int J Nurs Pract. 2014 Oct;20(5):549–60.
  • Lee A. Radiation Therapy Combined With Hormone Therapy for Prostate Cancer. Semin Radiat Oncol. 2006 Jan;16(1):20–8.
  • Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med. 2015 Jan 8;13:3.
  • Menichetti J, Villa S, Magnani T, Avuzzi B, Bosetti D, Marenghi C, et al. Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. Crit Rev Oncol Hematol. 2016 Dec;108:13–22.
  • Mohamad H, McNeill G, Haseen F, N’Dow J, Craig LCA, Heys SD. The Effect of Dietary and Exercise Interventions on Body Weight in Prostate Cancer Patients: A Systematic Review. Nutr Cancer. 2015 Jan 2;67(1):43–60.
  • Mottet N, Cornford P, van der Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer [Internet]. European Association of Urology; 2023 [cited 2023 Mar 30]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf
  • National Institute for Clinical Excellence CKS. How should I assess a person with suspected prostate cancer? [Internet]. How should I assess a person with suspected prostate cancer? 2022 [cited 2022 Jan 13]. Available from: https://cks.nice.org.uk/topics/prostate-cancer/diagnosis/assessment/#psa-testing
  • National Institute for Health and Care Excellence. Low dose rate brachytherapy for localised prostate cancer. Interventional procedure guidance 132. 2005.
  • National Institute for Health and Care Excellence. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. 2021.
  • National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management [Internet]. 2021 [cited 2022 Dec 19]. Available from: https://www.nice.org.uk/guidance/ng131
  • National Institute for Health and Clinical Excellence. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. Interventional procedure guidance 174. 2006;
  • NHS England. Clinical Commissioning Policy: Brachytherapy dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer (adults) [Internet]. NHS England; 2021 [cited 2023 Mar 2]. Available from: https://www.england.nhs.uk/wp-content/uploads/2021/07/1831-Policy-for-publication-Final.pdf
  • Digital Rectal Examination [Internet]. Health A-Z. 2020 [cited 2022 Feb 14]. Available from: https://www.nhs.uk/conditions/rectal-examination/
  • Prostate cancer - Treatment [Internet]. nhs.uk. 2021 [cited 2023 May 15]. Available from: https://www.nhs.uk/conditions/prostate-cancer/treatment/
  • Office for Health Improvement and Disparities. Advising men without symptoms of prostate disease who ask about the PSA test [Internet]. 2022 [cited 2022 Dec 22]. Available from: https://www.gov.uk/government/publications/prostate-specific-antigen-testing-explanation-and-implementation/advising-well-men-about-the-psa-test-for-prostate-cancer-information-for-gps
  • Pettersson A, Johansson B, Persson C, Berglund A, Turesson I. Effects of a dietary intervention on acute gastrointestinal side effects and other aspects of health-related quality of life: A randomized controlled trial in prostate cancer patients undergoing radiotherapy. Radiother Oncol. 2012 Jun;103(3):333–40.
  • Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res. 2011 May 24;71(11):3889–95.
  • Ruane-McAteer E, Porter S, O’sullivan JM, Santin O, Prue G. Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. Psychooncology. 2017;26(10):1411–21.
  • Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder WJ, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer. 2016 Jan 2;23(2):101–12.
  • Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut. 2006 May 1;55(5):593–6.
  • Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, et al. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2015 Sep 1;121(17):3010–7.
  • Wedlake LJ, Shaw C, Whelan K, Andreyev HJN. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther. 2013 Jun;37(11):1046–56.
  • Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of Urinary Incontinence Following Prostatectomy: The Role of Physical Activity and Obesity. J Urol. 2010 Feb;183(2):629–33.
  • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: https://www.wcrf.org/wp-content/uploads/2021/02/prostate-cancer-report.pdf
  • Hashim U. Ahmed, Professor of Urology, Imperial College London, Chair of Urology & Consultant Urological Surgeon, Imperial College Healthcare NHS Trust
  • Oliver Hulson, Consultant Radiologist, Leeds Teaching Hospitals NHS Trust
  • Venkata Ramana Murthy Kusuma, Consultant Urologist, The Stokes Centre for Urology, Royal Surrey Hospital NHS Foundation Trust
  • Vineetha Thankappannair, Prostate Cancer Clinical Nurse Specialist, Cambridge University Hospital NHS Trust
  • Our Specialist Nurses
  • Our Volunteers.